Forbion Capital et al. back Dezima Pharma

US-based firm New Science Ventures also participated in this round of funding. The company has also been granted a €4.4m loan by Agentschap NL, an agency of the Dutch Ministry of Economic Affairs.

The fresh capital will be used to further the development of innovative drugs in the field of dyslipidemia, for the clinical development of Dezima's cholesteryl ester transfer protein (CETP) inhibitor, and to develop additional earlier-stage dyslipidemia assets.

Company
Dezima was founded in 2012 by John Kastelein, from the department of vascular medicine at the University of Amsterdam's Academic Medical Center.

It was seed-financed by Forbion Capital Partners and BioGeneration Ventures to develop novel products to treat dyslipidemic patients suffering from cardiovascular diseases.

People
Marco Boorsma is a partner at Forbion. Sander van Deventer is CEO of Dezima and a general partner at Forbion. Somu Subramanian is a partner at New Science Ventures.

Boorsma, Subramaniam and BioGeneration Ventures' Wil Hazenberg will join the board of directors of Dezima.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Early-stage
• Healthcare
• Now researching
• Netherlands